European Medicines Agency
- Dedicated webpage on COVID-19
EMA has put together a dedicated website which summarized information on COVID-19.
- EMA Communication: Reporting suspected side effects of medicines in patients with COVID-19
EMA and the national competent authorities are reminding healthcare professionals and patients with confirmed or suspected coronavirus disease (COVID-19) to report suspected side effects that they experience with any of the medicines they are taking.
European Directorate for the Quality of Medicines & HealthCare (EDQM)
- Information on licensed products as well as extemporaneous preparations which may be suitable for treatment of paediatric patients with COVID-19
The European Paediatric Formulary Working Party at the EDQM compiled existing knowledge on paediatric formulations for active substances which are under investigation for the treatment of COVID-19 as well as known authorised medicinal products. This information might also be useful for other patient groups. Information on Chloroquine, Hydroxychloroquine and Lopinavir/Ritonavir is currently available.
- EDQM's contributions to the protection of public health in the COVID-19 pandemic: latest information
EDQM shared information on the preparedness of the Directorate as well as on information that has been made available to address the COVID-19 pandemic.
The disclaimer for the EAHP COVID-19 Resource Centre can be found here
Last update: 17 November 2020